Potential new therapy of Rapalink-1, a new generation mammalian target of rapamycin inhibitor, against sunitinib-resistant renal cell carcinoma.

Kuroshima, Kazuki

Potential new therapy of Rapalink-1, a new generation mammalian target of rapamycin inhibitor, against sunitinib-resistant renal cell carcinoma. [electronic resource] - Cancer science May 2020 - 1607-1618 p. digital

Publication Type: Journal Article

1349-7006

10.1111/cas.14395 doi


Animals
Apoptosis--drug effects
Carcinoma, Renal Cell--drug therapy
Cell Cycle--drug effects
Cell Line, Tumor
Cell Movement--drug effects
Cell Proliferation--drug effects
Drug Resistance, Neoplasm--drug effects
Female
Humans
Kidney Neoplasms--drug therapy
Mice
Mice, Nude
Protein Kinase Inhibitors--pharmacology
Signal Transduction--drug effects
Sirolimus--analogs & derivatives
Sunitinib--pharmacology
TOR Serine-Threonine Kinases--antagonists & inhibitors